Growing evidence indicates that Alzheimer disease (AD) pathophysiological processes initiate decades before the onset of clinical signs and symptoms. Within the continuum of the disease, the symptomatic stage is preceded by a preclinical phase in asymptomatic individuals. Early biomarkers should inform on pathophysiological preclinical stages in cognitively unimpaired elderly individuals at-risk for AD.
This educational update aims at giving an overview of the latest knowledge on the preclinical phase of Alzheimer’s Disease. Moreover, both presenters will discuss ethical aspects related to preclinical AD detection, prevention and involvement in pharmacological clinical trials.
